JP2011088897A5 - - Google Patents

Download PDF

Info

Publication number
JP2011088897A5
JP2011088897A5 JP2010253233A JP2010253233A JP2011088897A5 JP 2011088897 A5 JP2011088897 A5 JP 2011088897A5 JP 2010253233 A JP2010253233 A JP 2010253233A JP 2010253233 A JP2010253233 A JP 2010253233A JP 2011088897 A5 JP2011088897 A5 JP 2011088897A5
Authority
JP
Japan
Prior art keywords
apo
ligand
formulation
metal ions
divalent metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010253233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011088897A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011088897A publication Critical patent/JP2011088897A/ja
Publication of JP2011088897A5 publication Critical patent/JP2011088897A5/ja
Pending legal-status Critical Current

Links

JP2010253233A 1999-06-28 2010-11-11 二価の金属イオンを利用したApo−2リガンドの製造方法 Pending JP2011088897A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14134299P 1999-06-28 1999-06-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001506824A Division JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したApo−2リガンドの製造方法

Publications (2)

Publication Number Publication Date
JP2011088897A JP2011088897A (ja) 2011-05-06
JP2011088897A5 true JP2011088897A5 (https=) 2012-02-02

Family

ID=22495287

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001506824A Expired - Lifetime JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したApo−2リガンドの製造方法
JP2010253233A Pending JP2011088897A (ja) 1999-06-28 2010-11-11 二価の金属イオンを利用したApo−2リガンドの製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001506824A Expired - Lifetime JP5118796B2 (ja) 1999-06-28 2000-06-26 二価の金属イオンを利用したApo−2リガンドの製造方法

Country Status (12)

Country Link
US (3) US7855066B1 (https=)
EP (3) EP2339003A3 (https=)
JP (2) JP5118796B2 (https=)
KR (1) KR100674528B1 (https=)
CN (2) CN101633692A (https=)
AU (3) AU6338200A (https=)
CA (1) CA2377585A1 (https=)
ES (1) ES2392392T3 (https=)
IL (2) IL147029A0 (https=)
MX (1) MXPA01013236A (https=)
NZ (2) NZ537920A (https=)
WO (1) WO2001000832A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
EP1873244A3 (en) * 1999-06-02 2008-04-02 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
CN101633692A (zh) * 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
EP1501866A4 (en) * 2001-10-02 2006-02-08 Genentech Inc VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
EP1450847B1 (en) 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
EP2500032A1 (en) * 2002-06-24 2012-09-19 Genentech, Inc. APO-2 ligand/trail variants and uses thereof
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
BRPI0507233B8 (pt) 2004-03-11 2021-05-25 Genentech Inc processo para a produção de um polipeptídeo heterólogo em e. coli
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
MX2007001469A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN101287990B (zh) 2005-08-16 2012-07-04 健泰科生物技术公司 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
CN102775491A (zh) * 2011-05-09 2012-11-14 中国人民解放军第二军医大学 单链化的人凋亡素2配体三聚体蛋白质的制法和用途
CN102443055B (zh) * 2011-10-26 2017-07-28 浙江海正药业股份有限公司 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺
JP6355425B2 (ja) * 2014-05-20 2018-07-11 キヤノン株式会社 システムおよびその制御方法
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
AU2017234679A1 (en) * 2016-03-16 2018-08-30 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
CN111320384A (zh) * 2019-04-04 2020-06-23 株式会社小原 光学玻璃的制造方法
JP7429622B2 (ja) * 2020-08-26 2024-02-08 株式会社オハラ 光学ガラスの製造方法
CN115980241B (zh) * 2023-02-11 2025-01-07 烟台新特路新材料科技有限公司 一种硫代酯类抗氧化剂含量的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
WO1992003478A1 (en) 1990-08-17 1992-03-05 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AU1757092A (en) 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
US6387650B1 (en) * 1995-06-07 2002-05-14 Biocontrol Systems, Inc. Method and composition for detecting bacterial contamination in food products
DK1666591T3 (da) * 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
DE19547933A1 (de) * 1995-12-22 1997-06-26 Boehringer Mannheim Gmbh Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997046686A2 (en) 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
EP0929675A2 (en) 1996-10-03 1999-07-21 Biotherapies, Inc. Nucleotide and protein sequence of mammastatin and methods of use
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
AU8485098A (en) 1997-08-26 1999-03-16 Genentech Inc. Rtd receptor
JP2002508962A (ja) * 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Apo−2リガンド
SE9802454D0 (sv) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
CN101633692A (zh) * 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
WO2001018055A1 (en) 1999-09-10 2001-03-15 Eli Lilly And Company Flint analog compounds and formulations thereof
AU7053000A (en) 1999-09-10 2001-04-10 Eli Lilly And Company Flint compounds and formulations thereof
EP1501866A4 (en) * 2001-10-02 2006-02-08 Genentech Inc VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
EP1450847B1 (en) * 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
CN100500841C (zh) * 2005-10-10 2009-06-17 华东理工大学 一种表达可溶性trail蛋白的方法

Similar Documents

Publication Publication Date Title
JP2011088897A5 (https=)
JP2013522425A5 (https=)
JP2013546230A5 (https=)
JP2013540852A5 (https=)
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
JP2014500291A5 (https=)
EP2652711A4 (en) Coordination of animations between multiple applications or processes
JP2013140343A5 (https=)
MY173847A (en) Disinfectant compositions and uses thereof
JP2011510778A5 (https=)
WO2015038689A3 (en) Cationic antiseptic compositions
WO2010042633A3 (en) Naringenin complexes and methods of use thereof
JP2012500946A5 (https=)
MX341189B (es) Composicion liquida y acousa de bromfenaco, que tiene efectividad conservadora.
HK1203379A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
JP2011104357A5 (https=)
Doi et al. A two-country dynamic model of international trade and endogenous growth: Multiple balanced growth paths and stability
EP2628485A4 (en) New use of chemical ingredients in cynomorium as phytoestrogen
JP2011008097A5 (https=)
SI2699545T1 (sl) Novi amino-pirolinski derivati in uporaba le-teh pri preprečevanju in/ali zdravljenju metaboličnega sindroma
CL2013001596A1 (es) Proceso de purificacion y estabilizacion de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); y uso de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3).
EP2353384A3 (en) Disinfectant formulations that remain liquid at low temperature
JP2011084554A5 (https=)
JP2014159381A5 (https=)